TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prehabilitation in Esophageal Surgery (PRESS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent;~* Patients scheduled for Esophageal cancer resection with Ivor-lewis technique;~* Previous CT/RT neoadjuvant treatment;~* Possibility to perform a prehabilitation treatment of, at least, 4 weeks.~Exclusion Criteria:~* Patient refusal~* Comorbid medical, physical, and mental conditions that contraindicate exercise or oral nutrition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prehabilitation program (Type: EXPERIMENTAL): The patients included in the treatment group will follow a prehabilitation program, based on a physiotherapist, nutritionist and psychologist evaluation. All the treatments will be tailored according the characteristics of each single patient. The program will have a duration of, at least, 4 weeks.
- Control (Type: NO_INTERVENTION): The patients included in this group will, also, receive a basal evaluation by a physiotherapist, a nutritionist and a psychologist. These patients will not receive a tailored prehabilitation program and will be revaluated the day before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Relation Between Blood Concentration of Colchicine and Response to Colchicine Treatment in Gout Flare

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients (\> 18 years old) with gout flare defined by following items :~* Identification of sodium urate crystals in synovial fluid analysis~* Or gout flare diagnosis according to Nijmegen criteria (score \> 8/13)~  * Man (2 pts)~ * History of flare (2 pts)~ * Flare involving first metatarsophalangeal joint (2.5 pts)~ * Maximum of flare within 24h (0.5pt),~ * Redness (1 pt),~ * History of hypertension or cardiovascular diseases (1.5 pts),~ * Serum urate level \> 360 µmol/l during flare (3.5 pts)~* Duration of flare \< 48 h~* Monoarticular involvement~Exclusion Criteria:~* Hypersensitivity to colchicine, fexofenadine, benzodiazepine or the excipients of these drugs~* Contra-indication to colchicine : chronic kidney disease stage 4-5, severe hepatic impairment, treatment by macrolide antibiotics~* Used of pain-killers other than acetaminophen~* Involvement in another clinical trial with drug administration~* Illiteracy~* Pregnant woman or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pharmacokinetic study (Type: OTHER): all participants will undergo pharmacokinetic study and take colchicine (1.5 mg over 1 hour), midazolam (1 mg) and fexofenadine (120 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 11≤ Adolescents \< 20 years old~* Patient undergoing treatment of AIS by the MID-C system in daily practice~* Minimum of 35 degrees Cobb angle, confirmed by X-ray. Lenke type 1 or 5~* Flexible major curve, correction to below 30° at lateral bending.~* Risser sign of 1 to 5~* Appropriate candidate for posterior surgical approach as determined by surgeon~* Subject has good general health as determined by physician.~* Subject has no known hypersensitivity and allergies to Titanium~* Subject's guardian willing to sign a written Informed Consent Form (ICF)~Exclusion Criteria:~* Cobb angle over 60 degrees~* Other non-idiopathic scoliosis.~* AIS which is not defined as Lenke type 1 or 5~* Previous spine surgery.~* Known allergy to any component of the device.~* Known active systemic disease, such as AIDS, HIV, or active infection~* Systemic disease that would affect the subject's welfare or overall outcome of the study as determined by the physician.~* Mentally compromised as determined by the physician

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has given written Informed Consent.~* Histologically confirmed, unresectable, metastatic diffuse gastric cancer including carcinoma of the gastro-esophageal junction.~* No prior chemotherapy for gastric cancer except adjuvant and/or neo-adjuvant chemotherapy more than 12 months ago.~* Life expectancy of at least 3 months.~* Able to take medications orally.~* Eastern Cooperative Oncology Group performance status 0 to 1.~* Adequate organ function (bone marrow, kidney and liver).~Exclusion Criteria:~* Certain type(s) of non-measurable lesion(s), if the only one(s).~* Certain serious illness or medical condition(s).~* Lost greater than or equal to 10% of body weight in the 3 months proceeding signing the Informed Consent Form.~* Treatment with drugs interacting with S-1, 5-FU, or cisplatin.~* Pregnant or lactating female.~* Known hypersensitivity to fluoropyrimidines or cisplatin.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S-1+Cisplatin (Type: EXPERIMENTAL): Participants received S-1 25 milligrams per meter square (mg/m\^2) orally twice daily (BID) every 12 hours from Day 1 through Day 21, 1 hour before or after meal with a glass of water; followed by a 7-day rest period from Day 22 to Day 28 in a 28-day cycle. Participants received a single dose of cisplatin 75 mg/m\^2 as a 1- to 3-hour intravenous (IV) infusion on Day 1 following the morning dose of S-1 for a maximum of 8 cycles (each cycle of 28 days). Participants received study medication until progression of disease (PD), adverse event (AE), withdrawal of consent, or other reason for discontinuation, whichever happened earlier.
- 5FU+Cisplatin (Type: ACTIVE_COMPARATOR): Participants received 5-Fluorouracil (5-FU) 800 mg/m\^2 per 24 hours as continuous IV infusion over 120 hours from Day 1 through Day 5 followed by a 16-day rest period on Days 6 through 21 in a 21-day cycle. Participants received a single dose of cisplatin 80 mg/m\^2 as a 1- to 3-hour IV infusion on Day 1 prior to the start of the 5-FU infusion on Day 1 for a maximum of 8 cycles (each cycle of 21 days). Participants received study medication until PD, AE, withdrawal of consent, or other reason for discontinuation, whichever happened earlier.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Estrogen and Pelvic Floor Physical Therapy in Women With Symptomatic Mild Prolapse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women in good health aged 40-80~* Has symptoms of pelvic organ prolapse; answers yes to at least 1 of the following questions:~Do you feel or see a vaginal bulge? Do you feel pressure in the vagina?~* Meets POP-Q criteria on exam for stage I, II, or III prolapse~* Interested in PFPT for management of POP~* Normal mammogram within 1 year of enrollment~Exclusion Criteria:~* Prior surgery for prolapse or incontinence~* Other prior interventions for prolapse (e.g. pessary, PFPT)~* Previous bilateral salpingo-oophorectomy (women with 1 ovary will be eligible)~* Known liver dysfunction~* Connective tissue diseases known to affect collagen or elastin remodeling (including: Lupus, Rheumatoid Arthritis, Scleroderma, Sjogrens syndrome, Marfan syndrome, and Ehlers-Danlos syndrome)~* Unevaluated abnormal vaginal bleeding or abnormal pap smear in the previous year~* BMI \> 35 kg/m2~* Estrogen therapy (including birth control) in the previous year~* Current or prior breast or pelvic malignancy (ovarian, tubal, uterine, cervical or vaginal)~* Contraindication to hormone use (i.e. thromboembolic disorder, use of anti-coagulants, coronary artery disease, history of stroke)

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vaginal estrogen (Type: EXPERIMENTAL): Patients in the experimental group will receive vaginal estrogen cream
- Placebo cream (Type: PLACEBO_COMPARATOR): Patients in the comparison group will receive placebo vaginal cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mitigation of Postoperative Delirium in High-Risk Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with a history of cognitive impairment (CI) undergoing surgery at the Mount Sinai Health System.~* Attending physicians, resident physicians, and nurse anesthetists at the Mount Sinai Health System receiving CDS alerts during EHR system implementation.~Exclusion Criteria:~* Patients will be excluded if this not their first surgery since study start, if they do not have cognitive impairment based on EHR data, or if the surgery is for organ donation.~* There will be no exclusion criteria for providers or historical controls.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Clinical Decision Support (Type: EXPERIMENTAL): Clinical decision support alerts in the electronic health record directed towards anesthesiologists caring for patients with preexisting cognitive impairment.
- Standard of Care (Type: NO_INTERVENTION): No clinical decision support will appear, and standard of care procedures will take place.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Kidney transplant recipients \> 1 months post-transplant,~* No history of chronic diarrhea pre-transplant,~* \>3 watery/soft stools after transplant on at least 4 days in the week without anti-diarrheal for at least 2 weeks or using anti-diarrheals for at least 4 days in the week \> 2 weeks~* Subjects on at least 180mg twice a day of mycophenolate-sodium or 250 mg twice a day of cellcept~Exclusion Criteria:~* Diagnosis of any known colonic diseases (i.e. Crohn's disease, ulcerative colitis, ischemic colitis, Celiac disease), partial colonic resection, small bowel resection, history of cholecystectomy, Irritable Bowel Syndrome, fecal Incontinence, Bacterial overgrowth, infectious diarrhea (c difficle, cryptospora, giardia, isospora, Human Immunodeficiency Virus), Cytomegalovirus colitis~* Subjects with recent acute rejection treated with high dose steroids~* Subjects taking Boswellia serrata extract, over-the-counter herbs, cholestyramine, nonsteroidal salicylates (other than daily ASA)~* Subjects with active malignancy, liver cirrhosis, active peptic ulcer disease, known intolerance or resistance to budesonide, pregnancy, breast-feeding, mental retardation~* Unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Entocort EC (Type: EXPERIMENTAL): Subjects will take 6mg Entocort EC by mouth daily for 8 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will take 6mg matching placebo pill daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Panhematin for Prevention of Acute Attacks of Porphyria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged 18 years~2. Willing to provide written informed consent~3. A diagnosis of acute intermittent porphyria, hereditary coproporphyria or variegate porphyria confirmed by the following criteria, which are based on the criteria for enrollment in the Longitudinal Study of the Porphyrias Consortium. For each type of porphyria, the inclusion criteria are based on 1) clinical features, 2) biochemical findings, as documented by laboratory reports (or copies) of porphyria-specific testing, and 3) molecular studies to identify a mutation in a porphyria-related gene. Equivocal biochemical measurements may require confirmatory testing. Testing for a disease-causing mutation must be attempted, but an identified mutation is not essential for enrollment, since it is known that a mutation cannot be found in a small fraction (\<5%) of biochemically proven cases of porphyria. Subjects will (1.) have had frequent attacks in the past, with symptoms such as abdominal, back and/or limb pain and diagnosed after exclusion of other causes, and (2.) be on hemin prophylaxis for prevention of frequent attacks. It is expected that they will have had 6 or more attacks in one year before starting hemin prophylaxis.~Exclusion Criteria:~1. Symptoms such as abdominal, back or limb pain are explained by another condition, as judged by the investigator~2. Known or suspected allergy to Panhematin™ or related products~3. A known or suspected allergy to human albumin~4. Any disease or condition that the investigator judges would lead to an unacceptable risk to the patient or interfere with the successful collection of data for the trial~5. Previous randomization in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hemin for injection (Type: EXPERIMENTAL): Double blind doses of Panhematin 4 mg/kg body weight reconstituted with 25% human albumin and infused over at least one hour.
- Placebo (Type: PLACEBO_COMPARATOR): A double blind dose of saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Management of Type 2 Diabetes After Gastric Bypass Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) \> 35,~* Insulin-requiring T2DM,~* Age \>18yr,~* Having undergone gastric bypass surgery,~* HbA1C \>8%~Exclusion Criteria:~* Non-insulin requiring T2DM,~* HbA1C \<8%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Actrapid insulin (Type: EXPERIMENTAL): Intensive glycaemic control Intervention: Actrapid insulin
- Actrapid insulin+Gloucose (Type: ACTIVE_COMPARATOR): conventional glycaemic control Intervention: Actrapid insulin+Glucose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: EndoPredict® Extended Endocrine Trial (EXET)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female~* At least 18 years of age at time of enrollment~* Able to provide informed consent~* ER+, HER2- breast tumor~* Stage T1-T3~* Currently receiving endocrine therapy~* Are between 4 and 6.5 years post-invasive breast cancer diagnosis~* Have all available information to produce an EPclin score, including treatment-naïve tumor stage, nodal status, and sufficient amount of remaining tissue from biopsy or resection to perform genomic testing (section 9)~* Patient and physician are willing to consider a change in endocrine therapy~Exclusion Criteria:~* Metastatic disease or currently active additional cancer diagnosis (except non- melanoma skin cancer) or any second primary breast cancer (includes ductal and/or lobular carcinoma in situ)~* Patient received systemic chemotherapy within 1 year of enrollment~* Currently enrolled in an interventional clinical trial or other clinical trial that precludes freely making decisions regarding extended endocrine therapy~* More than 3 positive nodes~* Received neo-adjuvant treatment (new-adjuvant chemotherapy or neo-adjuvant endocrine therapy)~* Are beyond 7 years post-breast cancer diagnosis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with primary invasive ER+ HER2- breast cancer (Type: None): Distant recurrence-free survival (DRFS) between years 5 and 10 post-diagnosis of women with ER+, HER2- breast cancer who are classified as low risk according to their EPclin score and who did not receive extended endocrine therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Anaesthetic Methods for Total Knee Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a diagnosis of rheumatoid or osteoarthritis and listed for a primary total knee replacement.~* Participant is willing and able to give informed consent for participation in the study.~* Male or Female, aged between 18 and 85 years.~* American Society of Anesthesiologists (ASA) score I-III~* Able (in the clinical staff's opinion) and willing to comply with all study requirements.~* Willing to allow his or her General Practitioner and consultant, if appropriate, to be noti-fied of participation in the study.~Exclusion Criteria:~* Patient refusal~* Chronic pain (defined as consumption of \>480mg codeine/24hrs or ANY regular strong opiate consumption by the oral/transdermal route)~* Patients aged \<18 or \>85~* ASA score \>III~* Body mass index (BMI) \>35~* Lacking mental capacity to give consent to enter trial/undergo surgery~* Contraindications to catheter placement (coagulopathy , systemic sepsis or infection at placement site, pre-existing neuropathy) or any other component to the study treatment pathway.~* Participant who is terminally ill~* Allergy/intolerance to study medications~* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Group F (Type: ACTIVE_COMPARATOR): Femoral nerve catheter delivering 0.0625% L- Bupivacaine: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
- Group A (Type: EXPERIMENTAL): Adductor canal catheter delivering 0.0625% L- Bupivacaine: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Risk of Intraventricular Hemorrhage With Flat Midline Versus Right-Tilted Flat Lateral Head Positions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Born at the three study NICUs.~2. Gestational age \< 30 weeks.~Exclusion Criteria:~1. Lethal congenital anomalies.~2. Hypoxic ischemic encephalopathy.~3. Need external cardiac compression or epinephrine administration at birth.~4. Outborns.

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 2 Hours
- Healthy Volunteers: f

Study Arms:
- Flat midline head position (Type: OTHER): None
- Right flat lateral head position (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues